Table IV.
Summary matrix of IVF patient samples [Quinn's Advantage® Fertilization (HTF) Medium] treated with selected compound(s).
| Sample ID | WHO category | #1 |
#26 |
#30 |
#36 |
#37 |
#38 |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TM | PM | TM | PM | TM | PM | TM | PM | TM | PM | TM | PM | ||
| Decreasing total motility | |||||||||||||
| 943 | WHO normal | ― | ― | ↓ | ― | ↓ | ― | ↓ | ― | ― | ― | ↓ | ― |
| 1232 | WHO normal | ― | ― | ― | ― | ― | ― | ― | ↓ | ― | ↓ | ||
| 1308 | WHO normal | ↑ | ― | ↑ | ― | ― | ― | ↑ | ― | ― | ↓ | ||
| 997 | WHO normal | ↓ | ↓ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ||
| 947 | WHO normal | ― | ↑ | ― | ↑ | ― | ↑ | ― | ― | ― | ― | ― | ↑ |
| 1212 | WHO normal | ↑ | ↑ | ↑ | ― | ↑ | ― | ― | ― | ↑ | ― | ||
| 939 | WHO normal | ― | ↑ | ↑ | ↑ | ― | ↑ | ― | ― | ↑ | ↑ | ― | ― |
| 985 | WHO normal | ― | ― | ― | ― | ― | ― | ― | ― | ― | ― | ― | ― |
| 1020 | WHO normal | ↑ | ― | ↑ | ― | ||||||||
| 944 | WHO normal | ― | ― | ↑ | ― | ― | ― | ― | ― | ↓ | ― | ↑ | ― |
| 1307 | WHO normal | ↑ | ― | ↑ | ↑ | ↑ | ― | ↑ | ― | ↑ | ― | ||
| 872 | WHO normal | ― | ― | ― | ― | ― | ― | ― | ↓ | ― | ↓ | ― | ↓ |
| 986 | WHO normal | ― | ― | ― | ― | ― | ↑ | ― | ― | ― | ↑ | ― | ↑ |
| 1227 | WHO normal | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ||
| 1018 | WHO normal | ↑ | ↑ | ↑ | ― | ||||||||
| 1234 | WHO normal | ↑ | ↑ | ↑ | ↑ | ↑ | ― | ↑ | ↑ | ↑ | ↑ | ||
| 1290 | WHO normal | ↑ | ― | ↑ | ↑ | ↑ | ― | ↑ | ― | ↑ | ― | ||
| 1298 | WHO normal | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ||
| 911 | WHO normal | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ― | ↑ | ― | ↑ | ― |
| 865 | WHO normal | ― | ― | ― | ― | ― | ― | ― | ― | ― | ― | ― | ― |
| 1302 | WHO normal | ↑ | ↑ | ― | ― | ― | ― | ― | ― | ↑ | ↑ | ||
| 867 | WHO normal | ― | ― | ― | ― | ↑ | ↑ | ― | ― | ↑ | ↑ | ↑ | ― |
| 919 | WHO normal | ↑ | ― | ― | ― | ||||||||
| 992 | WHO normal | ― | ― | ― | ― | ― | ― | ― | ― | ||||
| 937 | WHO normal | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ― | ↑ | ↑ | ↑ | ↑ | ↑ |
| 877 | WHO normal | ― | ― | ― | ↑ | ― | ↑ | ― | ― | ↑ | ↑ | ↑ | ↑ |
| 1273 | Borderline | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ||
| 1037 | Borderline | ― | ― | ↑ | ― | ||||||||
| 1019 | WHO normal | ↑ | ― | ↑ | ― | ||||||||
| 949 | Borderline | ― | ― | ― | ↑ | ― | ― | ― | ― | ↑ | ↑ | ↑ | ↑ |
| 991 | Borderline | ↑ | ↑ | ― | ― | ↑ | ↑ | ↑ | ↑ | ||||
| 891 | Low TM and PM | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ||||||
↑, Significant increase; ― no change; ↓, significant decrease; empty cell, drug was not used in the experiment. WHO normal: WHO normal limits for total motility (40%) and progressive motility (32%), borderline: borderline motility, low TM and low PM: both total and progressive motility are below the WHO normal limit. No entry means compound is not tested. Significance means SD do not overlap (TM: total motility, PM: progressive motility).